Aequus Pharmaceuticals 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Doug Janzen

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	11.8yrs
CEO 소유권	9.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Doug Janzen 의 보수는 Aequus Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-CA$3m
Jun 30 2024	n/a	n/a	-CA$3m
Mar 31 2024	n/a	n/a	-CA$3m
Dec 31 2023	n/a	n/a	-CA$3m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$3m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	CA$206k	CA$206k	-CA$3m
Sep 30 2022	n/a	n/a	-CA$3m
Jun 30 2022	n/a	n/a	-CA$2m
Mar 31 2022	n/a	n/a	-CA$2m
Dec 31 2021	CA$225k	CA$225k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$1m
Dec 31 2020	CA$212k	CA$212k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$2m
Jun 30 2020	n/a	n/a	-CA$2m
Mar 31 2020	n/a	n/a	-CA$3m
Dec 31 2019	CA$191k	CA$191k	-CA$3m
Sep 30 2019	n/a	n/a	-CA$3m
Jun 30 2019	n/a	n/a	-CA$3m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	CA$180k	CA$180k	-CA$3m
Sep 30 2018	n/a	n/a	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$4m
Dec 31 2017	CA$258k	CA$210k	-CA$4m

보상 대 시장: Canadian 시장에서 비슷한 규모의 회사에 비해 Doug 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Doug 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Doug Janzen (55 yo)

11.8yrs

테뉴어

Mr. Douglas Glen Janzen, also known as Doug, is Director of Elevate Farms Inc. from September 2022. Mr. Janzen has experience in banking investments and managing growth companies with a particular focus on...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Douglas Janzen	Chairman	11.8yrs	데이터 없음	9.46% CA$ 125.5k
Marc Lustig	Independent Director	3.8yrs	CA$3.72k	5.21% CA$ 69.2k
Christopher Clark	Director	9.9yrs	CA$3.72k	데이터 없음
Iqbal Ahmed	Chairman of Strategic Advisory Board	6yrs	데이터 없음	데이터 없음
Anne Stevens	Director	9.9yrs	CA$3.72k	데이터 없음
Rosa Braga-Mele	Member of Strategic Advisory Board	6yrs	데이터 없음	데이터 없음
Vikram Lekhi	Member of Strategic Advisory Board	6yrs	데이터 없음	데이터 없음
Ken Patterson	Member of Strategic Advisory Board	6yrs	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: AQS 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

Aequus Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Health Check: How Prudently Does Aequus Pharmaceuticals (CVE:AQS) Use Debt?

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Is Aequus Pharmaceuticals (CVE:AQS) Using Debt Sensibly?

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Chairman & CEO recently bought CA$73k worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Chairman recently bought CA$58k worth of stock

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Chairman exercised options to buy CA$328k worth of stock.

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

New 90-day high: CA$0.28

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

New 90-day high: CA$0.23

Is Aequus Pharmaceuticals (CVE:AQS) Using Too Much Debt?

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

CEO 보상 분석

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령